Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 60 points (0.4%) at 16,603 as of Friday, May 23, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,002 issues advancing vs. 938 declining with 179 unchanged. The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 9.4%, Alnylam Pharmaceuticals ( ALNY), up 6.2%, Valeant Pharmaceuticals International ( VRX), up 1.5%, Allergan ( AGN), up 1.3% and Alexion Pharmaceuticals ( ALXN), up 1.0%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Amgen ( AMGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Amgen is down $0.60 (-0.5%) to $114.26 on light volume. Thus far, 1.4 million shares of Amgen exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $113.56-$115.12 after having opened the day at $114.99 as compared to the previous trading day's close of $114.86. Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $85.9 billion and is part of the health care sector. Shares are up 0.7% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.